Company intelligence / Profile preview

Change Connect

Taicang/Suzhou, Jiangsu, Chinachangeconnect.ca ↗

Ownership: Private
Development stage: Other

Overview

Connect Biopharma develops therapies targeting chronic inflammatory diseases using T cell-driven approaches. Its lead program, rademikibart (anti–IL‑4Ra antibody), has shown promising results versus Dupixent in asthma and atopic dermatitis through completed Phase 2 studies. The company received favorable FDA feedback regarding potential U.S. Phase 3 trials but paused advancement pending strategic review and financing. All preclinical/discovery programs were halted to conserve cash. A second asset, the S1P1 modulator “icanbelimod,” targets ulcerative colitis but had no recent updates as of Q2 2024[2][4].

Therapeutic areas: DermatologyGastroenterologyPulmonology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Simcere Pharmaceutical (Greater China rights to rademikibart)Pfizer collaboration previously existed but was terminated in April 2024

Beyond the preview

Go deeper on Change Connect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Change Connect.

Explore the full profile